TABLE 3.
Immunohistochemical Expression in Clear Cell and Nonclear-cell Sarcomatoid RCC (n=28)
| Staining Grade |
||||||||
|---|---|---|---|---|---|---|---|---|
| Clear-cell RCC (n=24), No. (%) |
Nonclear-cell RCC (n=4), No. (%) |
|||||||
| Antibody | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 |
| CA9 | 2 (8) | 1 (4) | 1 (4) | 20 (83) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| HIF-1α | 6 (25) | 3 (13) | 4 (17) | 11 (46) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| p-4E BP1* | 8 (35) | 2 (9) | 3 (13) | 10 (43) | 4 (100) | 0 (0) | 0 (0) | 0 (0) |
| p-S6* | 4 (18) | 2 (9) | 3 (9) | 14 (61) | 2 (50) | 2 (50) | 0 (0) | 0 (0) |
Staining not analyzed in 1 of 24 clear-cell tumors.
CA9 indicates carbonic anhydrase IX; HIF-1α, hypoxia-inducible factor-1α; p-4E BP1, phosphorylated eukaryotic initiation factor 4E-binding protein 1; pS6, phosphorylated protein S6 kinase 1; RCC, renal cell carcinoma.